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Provider-Level Variation in Smoking Cessation Assistance Provided in
the Cardiology Clinics: Insights From the NCDR PINNACLE Registry
Mayank Sardana, MBBS; Yuanyuan Tang, PhD; Jared W. Magnani, MD; Ira S. Ockene, MD; Jeroan J. Allison, MD, MS; Suzanne V. Arnold,
MD, MHA; Phillip G. Jones, MS; Thomas M. Maddox, MD, MSc; Salim S. Virani, MD, PhD; David D. McManus, MD, ScM
Background-—Studies show suboptimal provision of smoking cessation assistance (counseling or pharmacotherapy) for current
smokers attempting to quit. We aimed to identify smoking cessation assistance patterns in US cardiology practices.
Methods and Results-—Among 328 749 current smokers seen between January 1, 2013, and March 31, 2016, in 348 NCDR
(National Cardiovascular Data Registry) PINNACLE (Practice Innovation and Clinical Excellence)-afﬁliated cardiology practices, we
measured the rates of cessation assistance. We used multivariable hierarchical logistic regression models to determine provider-,
practice-, and patient-level predictors of cessation assistance. We measured provider variation in cessation assistance using
median rate ratio (the likelihood that the same patient would receive the same assistance at by any given provider; >1.2 suggests
signiﬁcant variation). Smoking cessation assistance was documented in only 34% of encounters. Despite adjustment of provider,
practice, and patient characteristics, there was large provider-level variation in cessation assistance (median rate ratio, 6 [95% CI,
5.76–6.32]). Practice location in the South region (odds ratio [OR], 0.48 [0.37–0.63] versus West region) and rural or suburban
location (OR, 0.92 [0.88–0.95] for rural; OR, 0.94 [0.91–0.97] for suburban versus urban) were associated with lower rates of
cessation assistance. Similarly, older age (OR, 0.88 [0.88–0.89] per 10-year increase), diabetes mellitus (OR, 0.84 [0.82–0.87]),
and atrial ﬁbrillation (OR, 0.93 [0.91–0.96]) were associated with lower odds of receiving cessation assistance.
Conclusions-—In a large contemporary US registry, only 1 in 3 smokers presenting for a cardiology visit received smoking
cessation assistance. Our ﬁndings suggest the presence of a large deﬁcit and largely idiosyncratic provider-level variation in the
provision of smoking cessation assistance. ( J Am Heart Assoc. 2019;8:e011307. DOI: 10.1161/JAHA.118.011307.)
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C igarette smoking is a modiﬁable risk factor for cardio-vascular disease (CVD), and smoking cessation leads to
2- to 3-fold reduction in the risk for incident CVD and
mortality within 5 years of smoking cessation.1–5 Despite the
clear beneﬁts of smoking cessation and availability of
effective cessation therapies,6 nationally representative data
from community-based samples suggest that only 1 in 3
smokers report receiving smoking cessation assistance
(counseling and/or pharmacotherapy) while attempting to
quit.5 Patient-survey based studies have similarly revealed a
large deﬁcit in the provision of smoking cessation assistance
in outpatient clinics,7–10 which matches up with the docu-
mentation of assistance in the electronic medical records.11
Even in clinical trial settings (which inherently bring in the bias
because of better clinical practice), the assistance rates have
been reported to be low.12
The lack of familiarity with smoking cessation guidelines,
inadequate reimbursement for counseling, and physician’s own
smoking status have been identiﬁed in smaller single-center
studies as the provider-level factors associated with poor
adherence to smoking assistance recommendations.13 A recent
survey of nearly 150 US-based cardiologists conducted by the
American College of Cardiology acknowledged the presence of a
signiﬁcant deﬁcit in comfort of providers for referral to the
smoking cessation programs and prescription of evidence-based
pharmacotherapy to assist cessation attempts.14
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To date, no large contemporary studies have assessed
national smoking cessation assistance patterns using registry-
based data, which is inherently more likely to be represen-
tative of “real-world” practice patterns as compared with
survey data. The NCDR (National Cardiovascular Data
Registry’s) PINNACLE (Practice Innovation and Clinical Excel-
lence) is the largest outpatient cardiovascular registry in the
world.15 PINNACLE continuously collects data from the
outpatient cardiology visits at the participating sites using
validated mapping algorithms. We performed a cross-
sectional analysis leveraging the PINNACLE data to (1)
measure the rates of smoking cessation assistance provided
to current smokers; (2) identify the predictors of smoking
cessation assistance; and (3) measure provider-level variation
in cessation assistance after adjusting for provider, practice,
and patient characteristics.
Methods
In accordance with the NCDR policies, data, methods used in
the analysis, and materials used to conduct the research will
not be made available by the authors. A requisition to obtain
the data can be directly submitted to NCDR for purposes of
reproducing the results or replicating the procedure.
Study Sample
The sample for our study was derived from the NCDR
PINNACLE registry. A total of 348 US ambulatory cardiology
practices currently voluntarily participate in the PINNACLE
registry. Data are collected prospectively using a validated
electronic medical record mapping algorithm that captures a
variety of relevant data elements such as demographics,
medical conditions, physical examination ﬁndings, medica-
tions, laboratory values, diagnostic testing, and interven-
tions.16 Additionally, practice characteristics such as practice
location (US Census region,17 rural versus suburban versus
urban location), and provider type (physician versus advanced
practice provider) are collected. The St Luke’s Mid-America
Heart Institute (Kansas City, MO) performs periodic audits to
ensure the validity and quality of collected data. Waiver of
written informed consent and authorization for this study was
granted by Chesapeake Research Review Incorporated.
Figure 1 depicts the ﬂowchart for development of a sample
for our current study. Brieﬂy, all the electronic medical
records for patients seen in US cardiology practices (irre-
spective of the reason for presentation) enrolled in the
PINNACLE registry from January 1, 2013, to March 31, 2016,
were screened using the algorithm to select the most recent
encounters of patients for whom smoking cessation was
assessed during the encounter and who were identiﬁed as
“current smokers.” A total of 329 536 records were identiﬁed
as the most recent encounters for current smokers. Because
of 1 or more missing variables, 787 (0.24%) records were
excluded. Therefore, our ﬁnal sample size was 328 749
unique clinical encounter records across 348 practices
participating in the PINNACLE registry.
Outcome Variables
For purposes of our analyses, the NCDR PINNACLE registry
v1.5 data collection form was used.16 The PINNACLE
electronic medical record mapping algorithm has been
validated to search for keywords pertaining to evidence-
based methods of smoking cessation counseling (eg, encour-
age to set a quit date, discuss medications, or refer to
smoking cessation treatment).6 If any of the validated
keywords are noted in the encounter record, it prompts a
“yes” response to the “smoking cessation counseling pro-
vided” data element. Additionally, those encounters with a
“yes” response to “bupropion,” “nicotine replacement ther-
apy,” or “varenicline”18 data elements were identiﬁed as the
ones that received pharmacotherapy (in addition to the
counseling). If the response to the above data elements was
“no,” we considered those encounters as the ones in which
smoking cessation assistance was not documented.
Predictor Variables
Predictor variables in our analyses included (1) provider type
(physician versus advanced practice providers), (2) practice
characteristics (practice region and urbanity), (3) patient
demographics (age, sex), and (4) medical comorbidities
Clinical Perspective
What Is New?
• Of all current smokers who were seen in the outpatient
cardiology practices enrolled in the PINNACLE (Practice
Innovation and Clinical Excellence) registry, only 1 in 3
received smoking cessation assistance.
• Despite adjusting for various predictors, a large provider-
level variation in smoking cessation assistance persisted.
What Are the Clinical Implications?
• Our ﬁndings provide real-world data on the large deﬁcit and
largely idiosyncratic provider-level variation in the smoking
cessation assistance practices.
• These ﬁndings call for immediate action from providers and
public health organizations to improve the adherence to the
provision of smoking cessation assistance in outpatient
cardiology practices.
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(hypertension, diabetes mellitus, dyslipidemia, coronary artery
disease, peripheral arterial disease, transient ischemic attack
(TIA) or cerebrovascular accident, heart failure, atrial ﬁbrilla-
tion or ﬂutter, and prior vascular intervention). Provider type
was categorized as physician versus advanced provider
practitioners (physician assistants and nurse practitioners)
on the basis of national provider identiﬁcation enumeration.19
Practice region was categorized on the basis of the 4 US
Census regions (Northeast, Midwest, South, and West).17 A
signiﬁcant proportion of encounters in the PINNACLE registry
have the race and insurance status missing. Therefore, we
decided to not include those variables in our analyses.
Statistical Analyses
Baseline characteristics are presented as meansSD for
continuous variables and as numbers and percentages for
categorical variables. We utilized multilevel hierarchical logis-
tic regression to models to measure (1) the provider-level
variation in smoking cessation assistance, and (2) the
association of the predictor variables with smoking cessation
assistance. To measure the magnitude of provider-level
variation, median rate ratio (MRR) was calculated. MRR
estimates the probability that 2 randomly selected patients
with similar characteristics (covariates) receiving care from 2
different providers in practice with similar characteristics
(census region and urbanity) will receive varying treatment. By
deﬁnition, MRR is always >1, as MRR of 1 would suggest no
variation between providers. MRR >1.20 reﬂects a signiﬁcant
variation in practice.20 In the ﬁrst regression model (empty
model), provider number was included as a random effect
variable to estimate the variation in smoking cessation
assistance between providers. The second regression model
included practice characteristics (census region and urbanity)
and provider type (physician versus advanced practice
providers) as ﬁxed-effect variables. The third regression
model additionally included patient-level variables (age, sex,
hypertension, diabetes mellitus, dyslipidemia, coronary artery
disease, peripheral arterial disease, TIA or cerebrovascular
accident, heart failure, atrial ﬁbrillation or ﬂutter, and prior
vascular intervention). No signiﬁcant collinearity was identi-
ﬁed among various predictive variables. A 2-tailed P≤0.05 was
considered signiﬁcant. MRR was calculated with each
regression model as a measure of residual provider-level
variation with inclusion of the various provider, practice, and
patient characteristics. SAS version 9.4 (SAS Institute, Cary,
NC) was used to perform analyses.
Results
The baseline patient, provider, and practice characteristics of
the study sample are presented in Table 1. Our sample
consisted of clinical encounters of middle-aged patients with
a slight male predominance (mean age, 5716 years; 54%
2,138,752 most recent clinical 
encounters for patients in which the 
smoking status was documented 
(01/01/2013 – 03/31/2016) 
329,536 current smokers
328,749 encounters included for 
analyses
112,884 encounters with smoking 
cessation assistance
215,865 encounters without smoking 
cessation assistance
11,223 encounters 
with both smoking 
cessation counseling 
and pharmacotherapy
101,661 encounters 
with smoking 
cessation counseling 
but no
pharmacotherapy
787 encounters with one 
or more missing 
variables
Figure 1. Flowchart depicting development of study sample.
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male). There was a high prevalence of the cardiovascular risk
factors, such as hypertension (61%), dyslipidemia (54%) and
diabetes mellitus (20%). Nearly 1 in 3 patients had a diagnosis
of coronary artery disease, whereas 7% had a diagnosis of TIA
or ischemic stroke. The majority of patients were seen by a
physician provider (93%). The majority of encounters in our
sample (current smokers) were generated from the cardiology
practices located in the South Census region (64%).
Of 328 749 most recent encounters of current smokers,
smoking cessation assistance was documented in a third of
the encounters (n=112 884, 34%; Figure 1). Assessing the
rates of smoking cessation assistance using only the most
recent clinical encounters could potentially underestimate the
actual rates of smoking cessation assistance (eg, if the
assistance was provided during another clinical encounter in
close temporal proximity). Therefore, we measured the rates
of smoking cessation assistance during “any” clinical encoun-
ters during the study period (January 2013 to March 2016),
and the rates were not signiﬁcantly different from our results
using the last clinical encounters (33% versus 34%). Of
112 884 encounters in which smoking cessation assistance
was documented, smoking cessation pharmacotherapy
(bupropion, nicotine replacement therapy, or varenicline)
was prescribed in only 10% (11 223) of the encounters
(Table S1). In an unadjusted comparison of baseline charac-
teristics, smoking cessation assistance was more likely to be
documented in the clinical encounters of older male patients,
and for those with hypertension, dyslipidemia, diabetes
mellitus, coronary artery disease, peripheral arterial disease,
ischemic stroke/TIA, prior vascular intervention, heart failure,
and atrial ﬁbrillation or ﬂutter (Table 1). Smoking cessation
assistance was also more likely to be documented in
encounters by physician provider as well in those generated
from practices located in the Midwest, Northeast, or West
Census regions and urban or suburban location. Considerable
variation was noted in the provision of smoking cessation
assistance across the 348 practices included in the present
analysis.
Table 1. Baseline Patient-, Provider-, and Practice-Level Characteristics of Study Patients by Smoking Cessation Assistance
Variable, n (%) Unless Speciﬁed
Smoking Cessation Assistance
P ValueYes (N=112 884) No (N=215 865)
Patient-level characteristics
Age, y, meanSD 5914 5717 <0.001
Women 50 666 (44%) 101 438 (47%) <0.001
Hypertension 79 428 (70%) 119 847 (55%) <0.001
Diabetes mellitus 23 519 (21%) 42 657 (20%) <0.001
Dyslipidemia 73 652 (65%) 103 105 (48%) <0.001
Coronary artery disease 51 576 (46%) 65 214 (30%) <0.001
Peripheral arterial disease 21 614 (19%) 20 672 (10%) <0.001
TIA or ischemic stroke 10 624 (9%) 13 099 (6%) <0.001
Heart failure 18 866 (17%) 25 193 (12%) <0.001
Atrial fibrillation or flutter 17 158 (15%) 26 546 (12%) <0.001
Prior vascular intervention 18 250 (16%) 19 782 (9%) <0.001
Provider- and practice-level characteristics
Physician provider 106 113 (94%) 201 029 (93%) <0.001
US Census region
Northeast region 19 073 (17%) 24 296 (11%) <0.001
Midwest region 21 495 (19%) 24 161 (11%)
South region 61 877 (55%) 149 828 (69%)
West region 10 429 (9%) 17 580 (8%)
Urbanity
Rural 44 870 (41%) 95 853 (46%) <0.001
Suburban 43 121 (39%) 76 592 (37%)
Urban 22 493 (20%) 35 889 (17%)
TIA indicates transient ischemic attack.
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In a logistic regression model including the provider
number as a random effect, there was signiﬁcant variation
in smoking cessation assistance among providers, as evi-
denced by MRR of 6.65 (95% CI, 6.37–7.01, Figure 2). With
inclusion of the provider type and practice characteristics
(Census region, urbanity) in the regression model, provider-
level variation persisted (MRR, 6.3; 95% CI 6.04–6.64). With
inclusion of patient demographics and clinical variables in the
regression model, MRR was slightly attenuated, but a high
residual provider-level variation in smoking cessation assis-
tance remained (MRR, 6; 95% CI, 5.76–6.32).
Although the predictive variables in the ﬁnal multivariable
regression model accounted minimally for the large provider-
level variation, we observed signiﬁcant association of various
variables with smoking cessation assistance (Table 2). Female
sex (odds ratio [OR], 1.18; 95% CI, 1.16–1.21), history of
hypertension (OR, 1.28; 95% CI, 1.25–1.31), dyslipidemia (OR,
1.49; 95% CI, 1.45–1.52), coronary artery disease (OR, 1.28;
95% CI, 1.25–1.32), peripheral arterial disease (OR, 1.73; 95%
CI, 1.68–1.78), TIA or ischemic stroke (OR, 1.14; 95% CI,
1.10–1.18), prior vascular intervention (OR, 1.04; 95% CI,
1.01–1.08), heart failure (OR, 1.06; 95% CI, 1.03–1.10) and
practice location in Midwest region (OR, 1.61 versus West
region; 95% CI, 1.18–2.21) were associated with higher odds
of smoking cessation assistance documentation. On the
contrary, older age (OR, 0.88 per 10-year increase; 95% CI,
0.88–0.89), history of diabetes mellitus (OR, 0.84; 95% CI,
0.82–0.87), atrial ﬁbrillation (OR, 0.93; 95% CI, 0.91–0.96),
and practice location in South Census region (OR, 0.48 versus
West region; 95% CI, 0.37–0.63) and rural (OR, 0.92 versus
urban; 95% CI, 0.88–0.95) or suburban location (OR, 0.94
versus urban; 95% CI, 0.91–0.97) were inversely associated
with smoking cessation assistance documentation. The
association of diabetes mellitus and atrial ﬁbrillation with
lower rates of smoking cessation assistance were contrary to
our hypothesis and could potentially be related to the
inclusion of prevalent cardiovascular diseases strongly asso-
ciated with smoking as a risk factor. We therefore performed
exploratory analyses leveraging multivariable-adjusted regres-
sion models where prevalent coronary artery disease, periph-
eral arterial disease, TIA/ischemic stroke, heart failure, and
prior vascular interventions were not included in the model.
The directionality of association of diabetes mellitus and atrial
ﬁbrillation with smoking cessation assistance in these models
was similar to that observed in our original multivariable-
adjusted regression models (Table S2).
Discussion
In this cross-sectional analysis of a large contemporary
sample of smokers receiving outpatient care in US cardiology
practices enrolled in the NCDR PINNACLE registry, we
observed low rates of smoking cessation assistance docu-
mentation. We observed a large variation in the provision of
Figure 2. Histogram of smoking cessation assistance rates across providers in PINNACLE. The
x axis represents percent of practices. The y axis represents assistance rates (0=assistance
provided to no smokers, 0.5=assistance provided to 50% of smokers, 1=assistance provided to
all smokers).
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smoking cessation assistance among providers, an observa-
tion that persisted after adjustment for measured provider,
practice, and patient characteristics. Older age, diabetes
mellitus, atrial ﬁbrillation, practice location in the South
Census region and rural or suburban areas were associated
with lower odds of receiving smoking cessation assistance.
Our ﬁndings suggest that a large deﬁcit in the provision of
smoking cessation assistance exists in the US ambulatory
cardiology practices and that the commonly measured
provider, practice, and patient characteristics account mini-
mally for the large provider-level variation in smoking
cessation assistance. These ﬁndings call for immediate action
from providers and public health organizations to improve the
adherence to the provision of smoking cessation assistance in
outpatient cardiology practices.
Cigarette smoking remains a common and modiﬁable risk
factor for CVD and non-CVDs.1,2 Smoking cessation at any age
is associated with a signiﬁcant reduction in the risk of CVDs
within ﬁrst 5 years of cessation.3,4,6 In an analysis from the
National Health Interview Survey conducted by the Centers for
Disease Control and Prevention, nearly two thirds of current
smokers intended to quit smoking and over half made attempts
at quitting within the previous year.5 However, only a third of
surveyed smokers reported receipt of counseling and/or
medications when trying to quit. The ﬁndings made in our
analyses are in line with the Centers for Disease Control and
Prevention ﬁndings. Only 1 in 3 encounters for current smokers
in the PINNACLE registry had documentation about the
provision of smoking cessation assistance. Our ﬁndings
suggest a signiﬁcant deﬁcit and opportunity for improvement,
especially when one considers the fact that a large number of
patients included in the PINNACLE registry were presenting for
a cardiology visit because of a preexisting CVD. In prior analyses
conducted from the National Ambulatory Medical Care Survey
data (1994–1996 and 2001–2003), only 1 in 4 to 1 in 5 current
smokers received cessation assistance in primary care and
specialty clinics.8,9. A more recent patient survey data from
primary care provider and HIV clinics reported slightly better
assistance rates (45%).7 Taken together, our ﬁndings suggest
that a signiﬁcant deﬁcit in smoking cessation assistance exists,
especially when one considers the fact that only 3.4% of current
smokers (ie, 10% of encounters in which smoking cessation
counseling was provided) received pharmacotherapy to assist
with cessation in our analyses.
Table 2. Provider-Level Variation and Association of Predictor Variables With Smoking Cessation Assistance
Variable
Model 1 Model 2 Model 3
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Median rate ratio 6.65 (6.37–7.01) 6.30 (6.04–6.64) – 6.00 (5.76–6.32) –
Physician provider* 1.18 (0.93–1.49) 0.18 1.18 (0.94–1.49) 0.16
Northeast vs West region 1.06 (0.78–1.45) 0.71 1.07 (0.79–1.45) 0.37
Midwest vs West region 1.68 (1.21–2.32) 0.002 1.62 (1.18–2.22) 0.003
South vs West region 0.47 (0.36–0.61) <0.001 0.48 (0.37–0.63) <0.001
Rural vs urban location 0.92 (0.89–0.95) <0.001 0.92 (0.88–0.95) <0.001
Suburban vs urban location 0.94 (0.91–0.96) <0.001 0.94 (0.91–0.97) <0.001
Age (per 10-year increase) 0.88 (0.88–0.89) <0.001
Female sex 1.18 (1.16–1.21) <0.001
Hypertension 1.28 (1.25–1.31) <0.001
Diabetes mellitus 0.84 (0.82–0.87) <0.001
Dyslipidemia 1.49 (1.45–1.52) <0.001
Coronary artery disease 1.28 (1.25–1.32) <0.001
Peripheral arterial disease 1.73 (1.68–1.78) <0.001
TIA or ischemic stroke 1.14 (1.10–1.18) <0.001
Heart failure 1.06 (1.03–1.10) <0.001
Atrial fibrillation or flutter 0.93 (0.91–0.96) <0.001
Prior vascular intervention 1.04 (1.01–1.08) 0.017
Model 1 (empty model) included provider number and was included as a random effect to estimate the variation in smoking cessation assistance among providers. Model 2 included
practice-level variables (practice number, Census region, and urbanity) and provider type (physician vs advanced practice providers) as ﬁxed effect variables. Model 3 additionally included
patient-level variables (age, sex, hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, peripheral arterial disease, TIA or cerebrovascular accident, heart failure, atrial
ﬁbrillation or ﬂutter, and prior vascular intervention). TIA inidcates transient ischemic attack.
*Physician provider vs advanced practice provider.
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In a survey of nearly 150 cardiologists by the American
College of Cardiology, the majority of participants reported
that they assess the readiness to quit and advise the patients
to quit smoking.14 However, just over two thirds felt
comfortable with referral to the smoking cessation programs
and only half felt comfortable prescribing pharmacotherapy to
assist in smoking cessation. Seventy-ﬁve percent of surveyed
participants identiﬁed the desire and need to learn more
about effective cessation therapies. In another recent Euro-
pean survey, Kotz et al21 surveyed 600 randomly selected
Dutch cardiologists regarding their smoking cessation assis-
tance patterns. Only a third of participants self-reported
providing smoking cessation counseling regularly, a remark-
ably similar rate to what was observed in our ﬁndings from the
PINNACLE registry.
The ambulatory clinic visit represents a valuable opportunity
for cardiology practitioners to emphasize smoking as an
important, modiﬁable CVD risk factor and to provide guidance
during a “teachable moment.” One of the unique ﬁndings from
our analyses is that commonly measured provider, practice,
and patient characteristics account minimally for the large
provider-level variation in smoking cessation assistance. The 2
aforementioned surveys suggest that one of the factors
responsible for low rates of smoking cessation assistance
observed in our study may include the fact that many providers
do not feel comfortable with pharmacotherapies for smoking
cessation, nor are they familiar with available counseling
resources. Although additional data from US providers on this
issue are lacking, in a recent survey of 371 French cardiologists,
the lack of familiarity with smoking cessation guidelines, lack of
adequate reimbursement for counseling, and, potentially, the
physician’s own smoking status were identiﬁed as the factors
mediating variation in smoking cessation assistance.13 Fur-
thermore, the lack of primary ownership in managing what are
perceived as “nonprimary CVD” medical problems, might also
play a role in creating confusion and the assumption that
smoking cessation assistance is being provided by primary care
physicians.22 Our ﬁndings provide actionable information for
providers and public health organizations to address this
concerning and largely idiosyncratic provider-level deﬁcit in
smoking cessation assistance. Some of the potential methods
that can be leveraged to address this deﬁcit are provider
training in smoking cessation counseling/motivational inter-
viewing/pharmacotherapy, clinical workﬂow improvement
(with assistance from paraprofessionals),23 patient education,
provision of adequate reimbursement, and, potentially, provider
incentive for smoking cessation assistance.24 Although we did
not assess for the inﬂuence of health insurance type on the
provision of smoking cessation assistance, smoking cessation
counseling was a quality metric emphasized by Medicare
(Physician Quality Reporting System) during our study period,
and therefore penalties were imposed for nondocumentation of
counseling for certain patients included in our sample.25
Further research is needed to determine whether reimburse-
ment payments/penalties for providing smoking cessation
assistance are exerting a positive effect on practice patterns.
In addition to the large deﬁcit and provider-level variation,
we observed regional and rural disparities in smoking
cessation assistance. Practice location in the South Census
region (versus the West region) and rural/suburban locations
(versus urban location) had an inverse association with
smoking cessation assistance. These disparities are concern-
ing considering the higher burden of CVD and CVD risk
factors (including smoking) in the South region and rural
America.26 Interestingly, provider type (physician versus
advanced practice provider) was not associated with smoking
cessation assistance. This ﬁnding supports the American
College of Cardiology’s recommendation regarding the train-
ing and incorporation of advanced practice providers in the
cardiovascular team–based model of healthcare delivery to
address the critical workforce shortage.27 We also identiﬁed
age-related disparities in the provision of smoking cessation
assistance despite the proven beneﬁt of smoking cessation
across all age groups in prior studies.28
Similarly, the patients with diabetes mellitus and atrial
ﬁbrillation were less likely to receive smoking cessation
assistance. Smoking has been associated with poor glycemic
control and increased risk for complications including CVD in
patients with diabetes mellitus.29–31 The inverse association
of smoking cessation assistance with diabetes mellitus
observed in our analyses might reﬂect a knowledge gap in
practitioners about the causal association of smoking with
diabetes mellitus and/or concern about worsening glycemic
control with smoking cessation.32 The prognostic importance
of cigarette smoking as a risk factor for atrial ﬁbrillation has
been recognized only in recent population-based studies.33–35
The inverse association of atrial ﬁbrillation with smoking
cessation assistance in our analyses likely limited under-
standing in providers about the association of smoking and
atrial ﬁbrillation. These ﬁndings provide important opportuni-
ties to address the knowledge gap among providers with
further educational efforts.
Strengths and Limitations
Our ﬁndings should be interpreted in context of the strengths
and limitations of the study. We used the detailed clinical data
collected from representative nationwide practices enrolled in
the PINNACLE registry. Our large sample size adds conﬁdence
to our ﬁndings. However, we acknowledge several limitations.
First, ascertainment of smoking cessation assistance relied
on either documentation of smoking cessation counseling or
prescription of smoking cessation pharmacotherapies. It is
plausible that in certain clinic encounters, counseling may
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have been provided but not documented in the clinic note.
However, it should be noted that the rates of smoking
cessation assistance in our study were comparable to those
reported by surveyed US cardiologists. Second, site partici-
pation in the PINNACLE registry is voluntary. The practice
selection bias inherent in PINNACLE means that the rates of
smoking cessation assistance are likely even lower in the non-
PINNACLE practices. Third, we did not obtain data on smoking
cessation rates and efﬁcacy of smoking cessation assistance.
Fourth, we did not adjust for social determinants of health
(race, income, education), which might affect the rates of
smoking cessation assistance. Fifth, regional differences in
health funding and policies might mediate some of the
variation in smoking cessation assistance patterns. Unfortu-
nately, these data were not collected in the PINNACLE
registry. However, we adjusted for random effect from the
practices in all our multivariable-models, which likely adjusted
for all practice-level effects, measured and unmeasured. Sixth,
the PINNACLE electronic medical record mapping algorithm
may not identify referrals to the smoking cessation programs,
such 1-800-QUITNOW. But the algorithm accurately captures
the cessation counseling that accompanies these referrals.
Therefore, we do not anticipate that the algorithm signiﬁcantly
underestimated the rates of smoking cessation assistance.
Conclusions
In this large cross-sectional analysis of a US ambulatory
cardiology registry with periodically audited high-quality data
and representative sites across the United States, we
identiﬁed low rates of smoking cessation assistance provided
to current smokers presenting for an outpatient visit. These
ﬁndings call to action and educate providers in the provision
of smoking cessation assistance. We identiﬁed both patient-
and practice-level predictors of receiving smoking cessation
assistance. However, despite adjusting for various predictors,
a large provider-level variation in smoking cessation assis-
tance persisted. Our ﬁndings form the basis for further
investigation into other contributors to smoking cessation
assistance, such as economic, social, environmental, and
organizational factors, that could enhance the rates of
smoking cessation assistance and reduce variation in care.
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Table S1. Baseline Patient, Provider and Practice-level Characteristics of 
Patients Stratified by Receipt of Smoking Cessation Pharmacotherapy. 
Only participants who received smoking cessation counseling are included here. N/A= not 
applicable.
Variable, n(%) unless specified Smoking Cessation Pharmacotherapy Standardized  
 Yes 
N=11223 
No 
N=101661 
Difference 
(%) 
Patient-level characteristics    
Age, years, mean±SD 56±13 59±14 19 
Women 6335 (56%) 43731 (43%) 27 
Hypertension  7079 (63%) 72349 (71%) 17 
Diabetes 2665 (24%) 20854 (21%) 8 
Dyslipidemia 7030 (63%) 66622 (66%) 6 
Coronary artery disease 4403 (39%) 47173 (46%) 15 
Peripheral arterial disease 1987 (18%) 19627 (19%) 4 
TIA or ischemic stroke 1194 (11%) 9430 (9%) 5 
Heart failure 1500 (13%) 17366 (17%) 10 
Atrial fibrillation or flutter 1232 (11%) 15926 (16%) 14 
Prior vascular intervention 1683 (15%) 16567 (16%) 4 
    
Provider & Practice-level 
characteristics 
   
Physician provider 10586 (94%) 95227 (94%) 2 
US Census region   N/A 
Northeast region 1631 (15%) 17442 (17%)  
Midwest region 1862 (17%) 19633 (19%)  
South region 6808 (61%) 55069 (54%)  
West region 922 (8%) 9517 (9%)  
Urbanity   N/A 
Rural 4481 (42%) 40389 (41%)  
Suburban 4325 (41%) 38796 (39%)  
Urban 1916 (18%) 20577 (21%)  
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Table S2. Association of Diabetes and Atrial Fibrillation with Smoking 
Cessation Assistance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Physician provider vs. advanced practice provider.  
 
Variable Odds Ratio  
(95% CI) 
P value 
Median rate ratio 6.12 (5.87 – 6.45) -- 
Physician provider* 1.19 (0.94 – 1.50) 0.15 
Northeast vs. West region 1.05 (0.77 – 1.43) 0.36 
Midwest vs. West region 1.66 (1.21 – 2.28) 0.002 
South vs. West region 0.47 (0.36 – 0.61) <0.001 
Rural vs. urban location 0.92 (0.89 – 0.95) <0.001 
Suburban vs. urban location 0.94 (0.91 – 0.97) <0.001 
Age (per 10 year increase)  0.91 (0.91 – 0.97) <0.001 
Female sex  1.15 (1.12 – 1.17) <0.001 
Hypertension  1.32 (1.29 – 1.35) <0.001 
Diabetes 0.91 (0.89 – 0.94) <0.001 
Dyslipidemia 1.64 (1.61 – 1.68) <0.001 
Atrial fibrillation or flutter 0.93 (0.91 – 0.96) <0.001 
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